Carthera announced today that it received FDA breakthrough device designation for its SonoCloud-9 system. Paris-based Carthera designed SonoCloud-9 for implantation in a skull window below the skin. Once in place, the device becomes invisible. When activated for a few minutes using a transdermal needle connected to an external control unit, it uses low-intensity pulsed ultrasound […]
Bioelectronic Medicine
MicroTransponder reports first commercial implantation of its stroke rehab neurostim system
MicroTransponder (Austin, Texas) recently announced the first commercial implantation of its Vivistim paired VNS system for chronic ischemic stroke rehabilitation. Dr. Charles Y. Liu, director of the University of Southern California Neurorestoration Center, and Dr. Jonathan J. Russin, director of the USC Neuro Revascularization Center, successfully placed the small Vivistim device under the skin of […]
NeuroMetrix revenues rise in Q1
NeuroMetrix (Nasdaq:NURO) shares dipped today on first-quarter results that saw losses despite year-over-year revenue growth. The Woburn, Massachusetts–based company posted losses of $958,562, or 14¢ per share, on sales of $2.3 million for the three months ended March 31, 2022, for a bottom-line slide deeper into the red on sales growth of 6.8%. NeuroMetrix’s biggest […]
Catheter delivery could enable better brain implants: Synchron’s neuroscience chief explains how
Synchron’s catheter delivery could make brain-computer interface technology simpler, safer and more accessible than the leading alternative: open-brain surgery. Officials at Synchron — developer of the catheter-delivered Stentrode brain-computer interface (BCI) implant — believe they’re the only BCI company tapping into blood vessels to capture signals from the brain. They say they’ve already enabled a […]
Study produces ‘promising results’ for Carthera’s SonoCloud tech for mild Alzheimer’s symptoms
Carthera announced positive results from a trial evaluating the safety and efficacy of the use of its SonoCloud technology. Results from the investigator-sponsored trial of SonoCloud in patients with mild Alzheimer’s Disease (AD) were published this week in the Alzheimer’s Research & Therapy Journal. Paris-based Carthera designed SonoCloud, an implantable 1 MHz ultrasound device, to be […]
Cala Health announces new chief commercial, financial officers amid leadership expansion
Cala Health announced today that it has expanded its leadership team with a number of appointments, including new chief commercial and financial officers. New executives joining the company — which develops bioelectronic medicines to provide new therapies for chronic diseases — hold experience from major players in the medtech space, including iRhythm, Johnson & Johnson, […]
NeuroMetrix reports Q4 losses
NeuroMetrix (NSDQ:NURO) today reported fourth-quarter results that included a bottom-line slide. The Woburn, Massachusetts–based neurostimulation technology developer posted losses of $1 million, or 15¢ per share, on sales of $1.8 million for the three months ended Dec. 31, 2021, for a bottom-line dip deeper into the red on sales growth of 0.6%. NeuroMetrix develops the […]
These medtech companies care a lot about research
They’re making glaucoma-treating stents, tumor-treating fields, coin-sized CGMs and more. Discover the medtech companies that spend the most on research as a percentage of revenue. The list comes from our annual Big 100 report, which examines the world’s 100 largest medical device companies and ranks them by revenue. (Check out our full Big 100 report […]
NIH launches $9.8M neuromodulation competition
The National Institutes of Health (NIH) announced today that it launched the first phase of its Neuromod Prize competition. Neuromod Prize, a $9.8 million competition, aims to accelerate the development of neuromodulation therapies. NIH seeks scientists, engineers and clinicians to submit novel concepts and clinical development plans to demonstrate solutions for stimulating the peripheral nervous […]
NeuroMetrix’s Quell wins FDA breakthrough designation to treat certain chemo side effects
NeuroMetrix (NSDQ:NURO) announced today that it received FDA breakthrough device designation for its Quell technology. Woburn, Massachusetts-based NeuroMetrix’s Quell garnered the breakthrough nod for reducing moderate-to-severe symptoms of chemotherapy-induced peripheral neuropathy (CIPN) that have persisted for at least six months following the end of chemotherapy. Shares of NURO were up 36.6% at $6.72 per share […]
NeuroOne gains Nasdaq listing
NeuroOne Medical Technologies (OTC:NMTC) announced that it was approved to uplist and begin trading on the Nasdaq market. Eden Prairie, Minn.-based NeuroOne expects trading to commence today at the open of the market, with the company trading under the “NMTC” ticker, according to a news release. The developer of surgical care options for patients suffering […]
